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 Pruritus (itch sensation) is the most common side effect associated with spinal 
administration of morphine given to humans for analgesia. A variety of agents have 
been proposed as antipruritics with poorly understood mechanisms and they are 
effective with variable success. Kappa opioid agonists possess several actions that are 
opposite to µ opioid agonists. We proposed to investigate the role of κ opioid receptors 
(KOR) in morphine-induced scratching and antinociception in monkeys. Scratching 
responses were counted by observers blinded to treatment. Antinociception was 
measured by a warm water (50oC) tail-withdrawal assay. Pretreatment with low doses of 
U-50488H (0.032-0.18 mg/kg, s.c.), a selective KOR agonist, dose-dependently 
suppressed the s.c. morphine dose-effect curve for scratching and potentiated s.c. 
morphine-induced antinociception. In addition, s.c. U-50488H attenuated i.t. morphine 
(10 and 32 µg)-induced scratching while maintaining or enhancing i.t. morphine-induced 
antinociception. The combination of s.c. or i.t. morphine with low doses of U-50488H did 
not cause sedation. More importantly, pretreatment with 3.2 mg/kg of nor-
binaltorphimine, a selective KOR antagonist, blocked the effects of s.c. U-50488H on 
both s.c. and i.t. morphine-induced scratching. These results indicate that activation of 
KOR attenuates morphine-induced scratching without interfering with antinociception in 
monkeys. This mechanism-based finding provides functional evidence in support of the 






Application of spinal opioids is one of the significant breakthroughs in pain 
management during the last two decades. For instance, intrathecal (i.t.) administration 
of morphine has been one of the most frequently used methods of analgesia following 
cesarean section and other surgical conditions. However, the most common side effect 
of spinal morphine is pruritus (i.e., itch sensation), which sometimes is severe and may 
lessen the value of spinal opioids for pain relief (Cousins and Mather, 1984; Ballantyne 
et al., 1988; Chaney, 1995; Kam and Tan, 1996). To date, there is no ideal antipruritic 
for patients. Several pharmacological agents have been proposed as antipruritics, but 
they are effective with variable success (Chaney, 1995; Kam and Tan, 1996). The 
mechanisms of proposed antipruritics are poorly understood, as there is a large 
deficiency in the basic research on spinal morphine-induced pruritus. This could be in 
part due to lack of reliable animal models. Although intracisternal administration of 
morphine evokes scratching responses in rodents, this behavior is not long-lasting and 
is only observed at small doses which do not produce profound antinociceptive effects 
(Tohda et al., 1997; Ko et al., 1999a). However, high doses of i.t. morphine produce 
allodynia-like behaviors, but no scratching, in rats. These behaviors are not reversed by 
opioid receptor antagonists (Yaksh and Harty, 1988).  
Recently, we have established an experimental model of itch in monkeys (Ko and 
Naughton, 2000). We found that i.t. administration of morphine dose-dependently 
produced long-lasting scratching responses and thermal antinociception in these 
animals, and this parallels clinical observations (Baraka et al., 1981; Bailey et al., 1993; 
Palmer et al., 1999). In addition, results obtained from this model confirm the finding 
that activation of central µ opioid receptors (MOR) produces scratching behavior 
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(Thomas et al., 1992, 1993; Tohda et al., 1997; Kuraishi et al., 2000). This non-human 
primate itch model provides a valuable opportunity for itch research. It allows us to 
conduct further studies to elucidate both the mechanisms and potential treatments of 
MOR-induced pruritus.  
Although opioid receptor antagonists are effective in attenuating i.t. morphine-
induced pruritus, they are not ideal therapeutic agents for patients. Several clinical 
studies have shown that spinal opioid-mediated analgesia was reversed when high 
doses of opioid receptor antagonists were administered to treat pruritus (Cohen et al., 
1992; Saiah et al., 1994; Wang et al., 1998). Our previous study also does not support 
opioid receptor antagonists for treatment of pruritus, because nalmefene produced an 
equal reduction of both scratching and antinociception in monkeys (Ko and Naughton, 
2000). Thus, one important goal of our studies is to identify specific pharmacological 
agents that can attenuate morphine-induced pruritus without attenuating analgesia.  
The κ opioid receptor (KOR) agonists appear to be a prominent potential target 
because several studies suggest that these agents may be therapeutically useful in this 
area. KOR agonists have antinociceptive effects, but possess several actions that are 
opposite to MOR agonists (e.g., Pan et al., 1998). One important finding is that 
behavioral profiles of monkeys with KOR agonist-dependence were qualitatively distinct 
from monkeys with morphine-dependence. Specifically, scratching is very prominent as 
a withdrawal sign in monkeys treated chronically with a selective KOR agonist, U-
50488H (Gmerek et al., 1987). Many symptoms of withdrawal from opioids appear to be 
opposite to the acute effects of agonist administration. Excessive scratching activity 
indicates that acute administration of KOR agonists may have antipruritic function. 
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Studies in rodents seem to support this notion, as systemic administration of KOR 
agonists inhibits scratching behavior evoked by a variety of pruritogenic agents without 
interfering with locomotor activity (Cowan and Gmerek, 1986; Cowan and Kehner, 1997; 
Togashi et al., 2002). Given that there is a possible functional interaction between MOR 
and KOR, it is pivotal to investigate whether activation of KOR can suppress the itching 
sensation while maintaining or augmenting the antinociceptive effects of i.t. morphine in 
primate species.  
The aim of this study was therefore to investigate the effects of systemic U-
50488H on s.c. and i.t. administration of morphine for both scratching and 
antinociception. Moreover, pretreatment with a selective KOR antagonist, nor-
binaltorphimine (nor-BNI), was conducted to verify whether KOR mediated the actions 














Materials and Methods 
Subjects 
Twenty-eight adult intact male and female rhesus monkeys (Macaca mulatta) with body 
weights ranging between 6.1 and 11.3 kg were used. They were housed individually 
with free access to water and were fed approximately 25 to 30 biscuits (Purina Monkey 
Chow; Ralston Purina, St. Louis, MO) and fresh fruit daily. All monkeys were previously 
trained in the warm water tail-withdrawal procedure and no monkey had exposure to 
opioids for one month before the present study. The monkeys were housed in facilities 
accredited by the American Association for the Accreditation of Laboratory Animal Care. 
The studies were conducted in accordance with the University Committee on the Use 
and Care of Animals in the University of Michigan and the Guide for the Care and Use 
of Laboratory Animals (National Academy Press, Washington DC, revised 1996).  
 
Procedures 
I. Scratching responses 
Scratching responses, inferred as an itch sensation (Ko and Naughton, 2000), were 
recorded on videotapes when monkeys were in their home cages. Each recording 
session was conducted for 15 min per test session. A scratch was defined as one short-
duration (< 1sec) episode of scraping contact of the forepaw or hind paw on the skin 
surface of other body parts. Scratches usually occurred repetitively at the same 
location. Scratching responses were counted by experimenters who were blinded to 
experimental conditions.  
II. Thermal antinociception 
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The warm water (50oC) tail-withdrawal assay was used to evaluate thermal 
antinociceptive effects. Briefly, monkeys were seated in primate restraint chairs, and the 
lower part of their shaved tails (approximately 15 cm) were immersed in a thermal flask 
containing water maintained at either 40, 50, or 55oC. Tail-withdrawal latencies were 
measured using a computerized timer by an experimenter who was blinded to 
experimental conditions. In each test session, monkeys were tested one to two times at 
three temperatures in a random order. If the monkeys did not remove their tails within 
20 sec (cutoff), the flask was removed and a maximum time of 20 sec was recorded. 
Test sessions began with control determinations at each temperature. In addition, 
sedation was evaluated by an experimenter blind to experimental conditions based on a 
modified sedation rating scale before the measurement of tail-withdrawal latencies in 
each test session (Ko et al., 1999b).  
III. Intrathecal injection 
Monkeys were positioned in primate restraint chairs and anesthetized by i.v. propofol 
(2.5-4.0 mg/kg for bolus infusion and 0.3-0.4 mg/kg/min for continuous infusion; 
AstraZeneca, Wilmington, DE). The lower back of the trunk was shaved and prepared 
sterilely with Betadine. A spinal needle (22G x 1-1/2, Becton Dickinson, Franklin Lakes, 
NJ) was inserted into the subarachnoid space between L4/L5 lumbar vertebra. Needle 
position was confirmed by a free flow of clear cerebrospinal fluid. A 1-mL saline solution 
of morphine (10 or 32 µg) was infused slowly through the spinal needle within 30 sec. 






The same group of monkeys, with the same number of each gender, were 
involved in both behavioral assays (i.e., scratching response and antinociception). 
However, both behavioral measurements were conducted in separate testing days. 
Each experimental condition associated with either behavioral assay was repeated one 
to two times, except with the antagonist study of nor-BNI. 
I. Effects of U-50488H pretreatment  
 The first part of this study was to investigate effects of U-50488H pretreatment on 
the dose-effect curves of systemic morphine for both scratching and antinociception. 
Eight male and female monkeys were used in all experiments, which were conducted 
once per week. Morphine (0.1-3.2 mg/kg) was administered subcutaneously in the back 
using a cumulative dosing procedure with a 35-min inter-injection interval. Recording of 
scratching activity was performed from 20 to 35 min after each injection. On a separate 
experiment, tail-withdrawal latencies were determined starting at 20-25 min after each 
injection. U-50488H (0.032-0.18 mg/kg) or vehicle (sterile water, 0.1 mL/kg) was 
administered subcutaneously at 15 min before the injection of the first dose of 
morphine. Pretreatment doses of U-50488H including the vehicle condition were given 
in a random order. 
II. Effects of U-50488H intervention  
 The second part of this study was to investigate whether U-50488H could 
reverse scratching subsequent to i.t. morphine administration. Two doses of morphine 
(10 and 32 µg) were chosen because these doses of i.t. morphine produced from 
moderate to maximum scratching responses (Ko and Naughton, 2000). Two groups of 
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monkeys were used (i.e., n=6 for one dose of i.t. morphine) for all experiments. 
Morphine was administered intrathecally with a 10-14-day inter-injection interval. 
Recording of scratching activity was conducted during 24-39th min and 54-09th min of 
each hour (i.e., 15 min per test session) for 3 hr after i.t. injection. During a separate 
experiment, tail-withdrawal latencies were measured at the same time points as the 
measurements of scratching. U-50488H (0.1-0.32 mg/kg) or vehicle (sterile water, 0.1 
mL/kg) was administered subcutaneously at 45 min after i.t. injection of morphine. 
Similarly, intervention doses of U-50488H were given in a random order. 
III. Antagonist effects of nor-BNI 
 The third part of the study investigated both the effects of nor-BNI alone and 
effects of nor-BNI on U-50488H modulation of behavioral effects produced by s.c. and 
i.t. morphine. First, nor-BNI (1-10 mg/kg) was administered subcutaneously to examine 
whether nor-BNI produced scratching responses. Doses of nor-BNI were chosen based 
on several antagonist studies indicating that they are systemically active doses in 
monkeys (Butelman et al., 1993, 1998). Three groups of monkeys were used (i.e., n=4 
for one dose of nor-BNI) for all experiments. Recording of scratching was conducted 
during 24-39th min and 54-09th min of each hour for 3 hr after administration of nor-BNI. 
In addition, recording was carried out again for 3 hr at 24 hr after nor-BNI 
administration.  
 Second, pretreatment with nor-BNI was performed to examine whether nor-BNI 
would block the effects of U-50488H on s.c. morphine dose-effect curve for scratching. 
Based on data in the first part of this study, s.c. U-50488H 0.1 mg/kg significantly 
suppressed the dose-effect curve of s.c. morphine-induced scratching. This 
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experimental condition was further used for the nor-BNI study. There were two groups 
of monkeys (n=6 per group) for all experiments. One group received s.c. vehicle (sterile 
water, 0.1 ml/kg) and the other group received s.c. nor-BNI 3.2 mg/kg. Before monkeys 
received either vehicle or nor-BNI, each group of monkeys established their own control 
values of effects of U-50488H on s.c. morphine dose-effect curve for scratching. Effects 
of U-50488H on the dose-effect curve of morphine were re-determined at 1, 7, 14, 21, 
28, and 35 days after treatment. These pretreatment time points were chosen based on 
studies indicating that peak KOR antagonist effects of nor-BNI were observed within the 
first two weeks after systemic administration in monkeys (Butelman et al., 1993, 1998). 
Third, pretreatment with nor-BNI was performed to examine whether nor-BNI 
would alter the effects of U-50488H on i.t. morphine-induced scratching and 
antinociception. Based on data in the second part of this study, s.c. U-50488H 0.1 
mg/kg significantly attenuated scratching and potentiated antinociception of i.t. 
morphine 10 µg. This experimental condition was further used for the nor-BNI study. 
There were two groups of monkeys (n=4 per group) for all experiments. One group 
received s.c. vehicle (sterile water, 0.1 ml/kg) and the other group received s.c. nor-BNI 
3.2 mg/kg. Before monkeys received either treatment, each group of monkeys 
established their own control values of effects of U-50488H on i.t. morphine (10 µg)-
induced scratching and antinociception. Effects of U-50488H on i.t. morphine-induced 
scratching and antinociception were re-determined at 1 day and 8 days after 





 Mean values (mean ± S.E.M.) were calculated from individual values for all 
behavioral endpoints. Comparisons were made for the same monkeys across all test 
sessions in the same experiment. Data were analyzed by a two-way analysis of 
variance followed by the Newman-Keuls test for multiple (post hoc) comparisons 
(p<0.05 for significance). As noted, we did not find a significant difference in effects 
induced by morphine alone or morphine with U-50488H between male and female 
monkeys, so mean values for all monkeys in the same condition were used for data 
analysis. For the dose-effect curve of s.c. morphine-induced antinociception, individual 
tail-withdrawal latencies in 50oC water were converted to percentage of maximum 
possible effect (%MPE). The formula of %MPE is defined as [(test latency – control 
latency)/(cutoff latency, 20 sec – control latency)] x 100. ED50 values were calculated by 
least-squares regression with the portion of the dose-effect curves spanning the 50% 
MPE. The 95% confidence limits (C.L.) were also determined (p<0.05). Mean ED50 
values were considered to be significantly different when their 95% C.L. did not overlap. 
 
Drugs 
 Morphine sulfate (Mallinckrodt, St. Louis, MO) was dissolved in saline. U-50488H 
(Sigma, St. Louis, MO) and nor-BNI (Div. Med. Chemistry, University of Michigan, Ann 
Arbor, MI) were dissolved in sterile water. For systemic administration, all compounds 
were administered subcutaneously in the back (i.e., around scapular region) at a 






I. Effects of U-50488H pretreatment 
Figure 1 illustrates effects of U-50488H on the morphine dose-effect curves for 
scratching and antinociception. Systemic administration of morphine dose-dependently 
produced scratching responses [F(3,21)=8.1; p<0.05]. As noted, there was no sex 
difference under this condition [F(1,3)=0.2; p>0.05]. The mean value of s.c. morphine (1 
mg/kg)-induced scratching was 375 ± 160 (S.E.M.) scratches in male monkeys (n=4); 
and the mean value for female monkeys (n=4) was 401 ± 104 scratches. The average 
number of scratches after a vehicle injection was 37 ± 13 for 15 min in this group of 
monkeys. Pretreatment with U-50488H attenuated the morphine dose-effect curve for 
scratching in a dose-dependent manner [F(3,21)=19.0; p<0.05]. Post hoc comparisons 
indicated that U-50488H from 0.032 to 0.18 mg/kg significantly attenuated the peak 
scratching effect of s.c. morphine 1 mg/kg (Figure 1, top panel).  
Systemic morphine also dose-dependently produced antinociception against 
50oC water. Mean ED50 (95% C.L.) value of s.c. morphine-induced antinociception was 
0.8 (0.5-1.4) mg/kg. As noted, mean ED50 value (0.6, 0.3-1.1 mg/kg) in male monkeys 
was not significantly different from the value (1.0, 0.3-3.2 mg/kg) in female monkeys. 
Pretreatment with U-50488H dose-dependently produced leftward shifts of the morphine 
dose-effect curve for antinociception (Figure 1, middle panel). In particular, s.c. U-
50488H 0.18 mg/kg significantly produced a 6-fold leftward shift for morphine-induced 
antinociception (ED50, 95% C.L.: 0.14, 0.1-0.3 mg/kg). In addition, pretreatment with U-
50488H did not increase sedation under these conditions [F(3,21)=1.5; p>0.05] (Figure 
1, bottom panel). 
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II. Effects of U-50488H intervention 
 Figure 2 illustrates effects of U-50488H on i.t. morphine-induced scratching and 
antinociception. Left panels show that s.c. U-50488H intervention dose-dependently 
attenuated i.t. morphine (10 µg)-induced scratching [F(3,15)=22.4; p<0.05]. Post hoc 
comparisons indicated that U-50488H (0.1-0.32 mg/kg) significantly attenuated 
scratching responses throughout the entire test sessions. In addition, s.c. U-50488H 
dose-dependently prolonged antinociception of i.t. morphine 10 µg [F(3,15)=27.2; 
p<0.05] and did not increase sedation rating under these conditions [F(3,15)=2.6; 
p>0.05].  
 Right panels illustrates effects of U-50488H on i.t. morphine (32 µg)-induced 
scratching and antinociception. I.t. morphine 32 µg produced more scratching 
responses and longer duration of antinociception than 10 µg of i.t. morphine. Similarly, 
s.c. U-50488H intervention dose-dependently attenuated i.t. morphine-induced 
scratching [F(3,15)=19.4; p<0.05] throughout the entire test sessions. In addition, s.c. U-
50488H maintained i.t. morphine-induced antinociception [F(3,15)=0.7; p>0.05] and did 
not increase sedation rating under these conditions [F(3,15)=2.7; p>0.05]. Lack of U-
50488H-induced enhancement of i.t. morphine (32 µg) may be due to a ceiling effect. 
III. Antagonist effects of nor-BNI 
 As noted, nor-BNI (1-10 mg/kg) did not produce scratching responses during the 
first 3 hr following s.c. administration [F(3,9)=3.4; p>0.05]. Nor-BNI also did not increase 
scratching responses at 24 hr after s.c. administration [F(3,9)=0.6; p>0.05] (data not 
shown). Figure 3 illustrates the antagonist effect of nor-BNI on the actions of U-50488H 
against s.c. morphine. Pretreatment with vehicle did not change the effect of U-50488H 
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on s.c. morphine dose-effect curve for scratching throughout the entire study period 
[F(6,30)=1.7; p>0.05] (Figure 3, panels A and B). In contrast, pretreatment with nor-BNI 
3.2 mg/kg significantly blocked attenuation of U-50488H on s.c. morphine dose-effect 
curve for scratching in a time-dependent manner [F(6,30)=4.3; p<0.05]. Post hoc 
comparisons indicated that nor-BNI 3.2 mg/kg significantly blocked the actions of U-
50488H 0.1 mg/kg from 1 day to 21 days following treatment (Figure 3, panels C and 
D).  
 Figure 4 illustrates the antagonist effect of nor-BNI on the actions of U-50488H 
against i.t. morphine. Pretreatment with vehicle did not change the effect of U-50488H 
on i.t. morphine (10 µg)-induced scratching responses [F(1,3)=0.2; p>0.05]. Vehicle also 
did not change the effect of U-50488H on i.t. morphine (10 µg)-induced antinociception 
[F(1,3)=0.3; p>0.05] (Figure 4, panels A and B). In contrast, pretreatment with nor-BNI 
3.2 mg/kg significantly blocked attenuation of U-50488H on i.t. morphine-induced 
scratching [F(1,3)=129; p<0.05]. Post hoc comparisons indicated that U-50488H 0.1 
mg/kg could not attenuate scratching for the entire sessions (Figure 4, panel C). In 
addition, nor-BNI pretreatment also blocked U-50488H-induced potentiation of i.t. 










 The present study demonstrated that systemic administration of low doses of U-
50488H could either prevent or attenuate morphine-induced scratching behavior. In 
particular, systemic U-50488H attenuated i.t. morphine-induced scratching while 
maintaining or enhancing morphine-induced antinociception. The actions of U-50488H 
were mediated by activation of KOR. This is the first study to validate the effectiveness 
of KOR activation in attenuating morphine-mediated scratching responses in primate 
species.  
 The dose-effect curve of s.c. morphine for scratching behavior can be 
established in monkeys. It is worth noting a large potency difference (i.e., ~1000 fold) 
between s.c. and i.t. morphine-induced scratching. The peak pruritic effect of s.c. 
morphine is observed approximately at 1 mg/kg, which equals to 10 mg total dose for 
monkeys with mean body weight of 10 kg in our laboratory. In contrast, the dose of i.t. 
morphine for producing a similar degree of scratching responses is approximately 10 µg 
(see Figure 2 in this study; Ko and Naughton, 2000). The hydrophilic property and 
associated difficulty crossing the blood-brain barrier of morphine may be part of the 
reason for this phenomenon (Herz and Teschemacher, 1971). It will be valuable to 
further compare the relative potency in evoking scratching between s.c. and i.t. 
administration of MOR agonists with different lipophilicities. Nevertheless, a large 
relative potency between s.c. and i.t. morphine-induced scratching may indicate that 
activation of central MOR mediates scratching behavior (Thomas et al., 1992, 1993; 
Tohda et al., 1997; Kuraishi et al., 2000).  
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 Pretreatment with U-50488H suppressed the s.c. morphine dose-effect curve for 
scratching. The interaction between U-50488H and morphine in scratching is not 
mediated by MOR antagonism, but may be a functional antagonism. KOR agonists 
possess several actions opposite to MOR agonists (e.g., Pan et al., 1998). The potential 
antipruritic action of KOR may counteract the pruritic action of MOR. The opposite 
functional interaction between MOR and KOR has been reported with other in vivo 
evidence. For example, KOR agonists produce diuretic effects and MOR agonists 
produce antidiuretic effects. It has been shown that full KOR agonists with MOR agonist 
activities, but not pure KOR agonists, have inverted U-shaped dose-effect curves for 
diuresis (Leander, 1984).  
Pretreatment with U-50488H potentiated morphine-induced antinociception as 
indicated by leftward shifts of the morphine dose-effect curve. Interestingly, another 
study in monkeys found that pretreatment with morphine produced a leftward shift of U-
50488H dose-effect curve for antinociception (Butelman et al., 1995). Several studies 
have shown that systemic administration of either MOR or KOR agonists produces 
antinociceptive effects in monkeys (Butelman et al., 1993, 1998; France et al., 1994; Ko 
et al., 1998, 1999b). Both MOR and KOR may produce antinociception through a 
common mechanism by disinhibition of pain inhibitory neurons (Ackley et al., 2001). It 
seems important to further investigate whether U-50488H enhances antinociception 
produced by other MOR agonists in monkeys.  
 Systemic administration of U-50488H attenuated i.t. morphine-induced scratching 
responses. More importantly, s.c. U-50488H maintained or prolonged i.t. morphine-
induced antinociception without enhancing sedation. As noted, doses of U-50488H (i.e., 
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0.032-0.32 mg/kg) used in the present study are low doses, which do not produce 
significant antinociception and sedation in monkeys when administered alone. Higher 
doses of U-50488H (i.e., ≤0.56-3.2 mg/kg) produce moderate to full antinociception in 
the presence of sedation and muscle relaxation (Butelman et al., 1993, 1998; France et 
al., 1994; Ko et al., 1998, 1999b). In addition, given combination of U-50488H with 
either s.c. morphine or i.t. morphine, monkeys did not have observable muscle 
relaxation. These results agree with the finding that KOR agonists inhibit scratching at 
doses that do not suppress locomotor activity and general behavior in rodents (Cowan 
and Kehner, 1997; Togashi et al., 2002). Nevertheless, 0.1 mg/kg of U-50488H is 
detectable for monkeys trained to discriminate KOR agonists (France et al., 1994). It is 
possible that KOR-mediated dysphoria may limit its therapeutic potential. Nevertheless, 
MOR-mediated euphoria may counteract KOR-mediated dysphoria. An opioid agonist 
with mixed actions of high efficacy on MOR and low efficacy on KOR may be an ideal 
candidate as an analgesic with low abuse liability. Unfortunately, to date, there is no 
such a compound available for experimental research in animals. Mixed MOR/KOR 
agonists such as butorphanol do not follow this profile, as butorphanol has low to 
medium efficacy on both MOR and KOR (Butelman et al., 1995). 
 Nor-BNI did not evoke scratching responses in monkeys immediately or 24 hr 
after systemic administration. This finding does not agree with the results of a rodent 
study indicating that nor-BNI-induced scratching behavior is partially mediated by the 
release of histamine (Kamei and Nagase, 2001). There are several factors that may 
contribute to this functional discrepancy across species. For example, there are species 
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differences in KOR regulation. A study has shown differences in KOR agonist-induced 
desensitization and phosphorylation between human KOR and rat KOR (Li et al., 2002).  
In addition, a newly developed KOR antagonist, GNTI, also produced profound 
scratching responses in mice. However, pretreatment with KOR agonists only partially 
attenuated GNTI-induced scratching, indicating a potential role of non-KOR (Cowan et 
al., 2002).  
 The KOR antagonist effect of s.c. nor-BNI can be clearly detected at 24 hr 
following administration and it lasts for 2-3 weeks in monkeys (Butelman et al., 1993, 
1998). The time course of nor-BNI-induced KOR antagonism in this study is similar to 
previous findings. Pretreatment with nor-BNI 3.2 mg/kg produced a 21-day antagonism 
for the actions of U-50488H on the s.c. morphine dose-effect curve for scratching 
(Figure 3). In addition, pretreatment with the same dose of nor-BNI completely blocked 
the actions of U-50488H on i.t. morphine-induced scratching and antinociception (Figure 
4). These results confirm that effects of U-50488H are mediated by KOR and may be a 
mechanism-based finding for KOR agonists as potential antipruritics. Future studies are 
needed to investigate the effects of i.t. administration of combination of morphine and U-
50488H to determine the sites of action of KOR agonists as antipruritics. Moreover, it is 
important to compare the effectiveness of KOR agonists with less ability to enter CNS 
with prototypic KOR agonist U-50488H as antipruritics (Cowan and Gmerek, 1986; 
Cowan and Kehner, 1997). 
Although morphine can release histamine from mast cells, this may not be its 
main mechanism of pruritus. Several studies have shown that antihistamines are not 
effective in relieving morphine-induced pruritus (Thomas et al., 1993; Dunteman et al., 
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1996; Kam and Tan, 1996). Moreover, not all MOR agonists produce histamine release 
in humans. Intravenous administration of MOR agonists, such as fentanyl, produced itch 
sensation, but they did not induce histamine release (Hermens et al., 1985; Flacke et 
al., 1987; Stellato et al., 1992). Although a class of spinothalamic tract neurons 
selectively sensitive to histamine has been identified (Andrew and Craig, 2001), it 
seems more pivotal to identify the sensory neurons in which MOR and KOR are co-
localized in primate species (Gutstein et al., 1998).  
 In summary, this study demonstrates the effectiveness of KOR activation in 
attenuating morphine-induced scratching responses in non-human primates. It may be 
useful to use KOR agonists to treat pruritus associated with spinal administration of 
MOR agonists in humans.  
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Figure 1. Effects of U-50488H pretreatment on systemic morphine dose-effect 
curves for scratching responses and antinociception. Top panel shows the effect of U-
50488H on s.c. morphine-induced scratching. Middle and bottom panels show the effect 
of U-50488H on s.c. morphine-induced antinociception and sedation, respectively. U-
50488H (mg/kg) was given subcutaneously at 15 min before the first dose of morphine. 
Each value represents mean ± S.E.M. (n=8). Symbols represent different experimental 
conditions for the same monkeys. The asterisk represents a significant difference from 
the vehicle condition (∗ p<0.05). 
 
Figure 2. Effects of U-50488H intervention on i.t. morphine-induced scratching 
responses and antinociception. Left panels show the effect of U-50488H on i.t. 
morphine (10 µg)-induced scratching, antinociception, and sedation. Similarly, right 
panels show the effect of U-50488H on i.t. morphine (32 µg)-induced scratching, 
antinociception, and sedation. Antinociception was measured by a warm water (50oC) 
tail-withdrawal procedure. U-50488H was given subcutaneously at 45 min after i.t. 
injection of morphine. Each value represents mean ± S.E.M. (n=6). Symbols represent 
different experimental conditions for the same monkeys. The asterisk represents a 
significant difference from the vehicle condition between time points 1 hr and 2.5 hr (∗ 
p<0.05). The symbol (#) associated with data points represents a significant difference 




Figure 3. The antagonist effect of nor-BNI on the actions of U-50488H against s.c. 
morphine. Panels A and B show the effect of s.c. vehicle pretreatment (PT) on the 
actions of U-50488H. Panels C and D show the effect of s.c. nor-BNI PT on the actions 
of U-50488H. U-50488H 0.1 mg/kg was given subcutaneously at 15 min before the first 
dose of morphine. The dose-effect curve (DEC) of morphine-induced scratching was 
determined at 1, 7, 14, 21, 28, 35 days after PT. Each value represents mean ± S.E.M. 
(n=6). CTRL represents the effects of U-50488H on the DEC of morphine-induced 
scratching before each group of monkeys (n=6) received either vehicle or nor-BNI. The 
asterisk represents a significant difference from the CTRL condition (∗ p<0.05). See 
Experimental Designs and Figure 1 for other details. 
 
Figure 4.  The antagonist effect of nor-BNI on the actions of U-50488H against i.t. 
morphine. Panels A and B show the effect of s.c. vehicle pretreatment (PT) on the 
actions of U-50488H. Panels C and D show the effect of s.c. nor-BNI PT on the actions 
of U-50488H. U-50488H 0.1 mg/kg was given subcutaneously at 45 min after i.t. 
injection of morphine. I.t. morphine (10 µg)-induced scratching and antinociception were 
determined at 1 and 8 days after PT, respectively. Each value represents mean ± 
S.E.M. (n=4). CTRL represents the effects of U-50488H on i.t. morphine-induced 
scratching and antinociception before each group of monkeys (n=4) received either 
vehicle or nor-BNI. The asterisk represents a significant difference from the CTRL 
condition (∗ p<0.05). See Experimental Designs and Figure 2 for other details. 




